ArticleInternational journal of biological sciences2023
G against Glioma: G protein inhibitory α subunit 2 (Gαi2) as a novel glioma target.
Article in International journal of biological sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Exosomes in the Chemoresistance of Glioma: Key Point in Chemoresistance.Journal of cellular and molecular medicine · 2025Review
- The Recent Research Progress of NF-κB Signaling on the Proliferation, Migration, Invasion, Immune Escape and Drug Resistance of Glioblastoma.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma is among the cancers with the highest mortality and morbidity. The complex biology and acquired chemoresistance create a continuous need for novel, effective therapies. In a recent report by Wang et al, an elegant bioinformatic analysis revealed potential functions and underlying chemopreventive mechanisms involving G protein inhibitory α subunit 2 (Gαi2), which activates NF-κB, a master transcription factor in the regulation of glioma. Given that NF-κB takes part in positive regulatory feedback loops during glioma development, Gαi2 is an attractive candidate for targeted therapies. This discovery unlocks new avenues towards understanding the biology of gliomagenesis as well as the discovery of novel targeted antiglioma agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.